The FDA pushed back review timelines for Eylea HD, classifying the submission as a major amendment, while Novo Nordisk acquired the manufacturer.
4 reports, 4 independent
Updated Aug 21
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA pushed back review timelines for Eylea HD, classifying the submission as a major amendment, while Novo Nordisk acquired the manufacturer.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Regeneron Pharmaceuticals
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- GuruFocus.comFDA Pushes Back Eylea HD Review; Regeneron Still Gains This article first appeared on GuruFocus. Regeneron (NASDAQ:REGN) picked up gains Tuesday after announcing that the FDA pushed back decision tim
- GlobeNewswireEYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Phar
- Pharmaceutical TechnologyManufacturing issues at Novo facility disrupt Regeneron drug review Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regul
- BioPharma DiveRegeneron cancer bispecific rejected again; Allogene discloses trial death This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPh